8OG0 image
Deposition Date 2023-03-17
Release Date 2024-03-27
Last Version Date 2024-11-06
Entry Detail
PDB ID:
8OG0
Keywords:
Title:
Crystal structure of MJF14-6-4-2 Fab fragment in complex with epitope peptide
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.71 Å
R-Value Free:
0.23
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Fab fragment heavy chain
Chain IDs:B (auth: H)
Chain Length:222
Number of Molecules:1
Biological Source:Oryctolagus cuniculus
Polymer Type:polypeptide(L)
Molecule:Fab fragment light chain
Chain IDs:A (auth: L)
Chain Length:216
Number of Molecules:1
Biological Source:Oryctolagus cuniculus
Polymer Type:polypeptide(L)
Molecule:Alpha-synuclein
Gene (Uniprot):SNCA
Chain IDs:C (auth: P)
Chain Length:5
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Structural basis of epitope recognition by anti-alpha-synuclein antibodies MJFR14-6-4-2.
NPJ Parkinsons Dis 10 206 206 (2024)
PMID: 39463404 DOI: 10.1038/s41531-024-00822-y

Abstact

Alpha-synuclein (α-syn) inclusions in the brain are hallmarks of so-called Lewy body diseases. Lewy bodies contain mainly aggregated α-syn together with some other proteins. Monomeric α-syn lacks a well-defined three-dimensional structure, but it can aggregate into oligomeric and fibrillar amyloid species, which can be detected using specific antibodies. Here we investigate the aggregate specificity of monoclonal MJFR14-6-4-2 antibodies. We conclude that partial masking of epitope in unstructured monomer in combination with a high local concentration of epitopes is the main reason for MJFR14-6-4-2 selectivity towards aggregates. Based on the structural insight, we produced mutant α-syn that when fibrillated is unable to bind MJFR14-6-4-2. Using these fibrils as a tool for seeding cellular α-syn aggregation, provides superior signal/noise ratio for detection of cellular α-syn aggregates by MJFR14-6-4-2. Our data provide a molecular level understanding of specific recognition of toxic amyloid oligomers, which is critical for the development of inhibitors against synucleinopathies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures